Jacoline E. C. Bromberg

Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort study Open

Lisa Berg, Joyce Wilbers, Filip De Vos, Mathilde C.M. Kouwenhoven, Antoinette Y. N. Schouten‐van Meeteren , et al. · 2025

Purpose Pilocytic astrocytomas are circumscribed WHO grade I gliomas that predominantly affect children, although they also occur in adults. While maximal safe resection is standard treatment, until recently chemotherapy was often used in …

P12.42.A EARLY [18F]FET PET-MRI FOLLOW-UP IN IDH-MUTANT GLIOMA PATIENTS TREATED WITH VORASIDENIB Open

Maarten M.J. Wijnenga, J.D. de Jong, Joost L.M. Jongen, Jacoline E. C. Bromberg, Walter Taal , et al. · 2025

BACKGROUND The IDH inhibitor vorasidenib has been made available in the Netherlands via a patient access program. Early markers of response would be highly valuable for clinical decision-making but are currently lacking. There is a growing…

90 | SEVEN‐YEAR FOLLOW‐UP OF THE IELSG42 “MARIETTA” PHASE II TRIAL: DURABLE REMISSIONS FOLLOWING MATRix/RICE INDUCTION AND THIOTEPA AUTOGRAFT IN SECONDARY CNS LYMPHOMA Open

Kate Cwynarski, Jeanette K. Doorduijn, Teresa Calimeri, Diva Baggio, A. Re , et al. · 2025

Development and validation of a clinical prediction model for hospitalization after emergency department admission in patients with cancer Open

Z Kaplan, David van Klaveren, Jason G.A. den Duijn, Rob J.C.G. Verdonschot, N. Wlazlo , et al. · 2025

Long-Term Follow-Up Results of Antiseizure Medication Withdrawal in Grade 2 and 3 Glioma Patients Open

Pim B. van der Meer, Melissa Kerkhof, Linda Dirven, Marta Fiocco, Maaike J. Vos , et al. · 2025

This study provides Class III evidence that withdrawal of ASM does not significantly increase the risk of recurrent seizures in patients with glioma with stable disease and no seizures for >1 year. Confidence intervals do not exclude a cli…

Clinical impact and safety of brain biopsy in unexplained central nervous system disorders: a real‐world cohort study Open

Robin W. van Steenhoven, Saba Ibrahim Salih, Juna M. de Vries, Ide Smets, Robert M. Verdijk , et al. · 2025

Objective A substantial part of central nervous system (CNS) disorders remains unexplained, despite various new and minimally invasive diagnostic techniques. Within this rapidly developing diagnostic field, the precise role of brain biopsy…

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Open

Andrés J.M. Ferreri, Gerald Illerhaus, Jeanette K. Doorduijn, Dorothee P. Auer, Jacoline E. C. Bromberg , et al. · 2024

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up Open

Andrés J. M. Ferreri, Gerald Illerhaus, Jeanette K. Doorduijn, Dorothee P. Auer, Jacoline E. C. Bromberg , et al. · 2024

Highlights This EHA‐ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS. The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow‐u…

Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review Open

Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet S. Ahluwalia , et al. · 2024

Background The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors. Methods The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisci…

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study Open

Jacoline E. C. Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven , et al. · 2023

Background Studies on the efficacy of rituximab in primary CNS lymphoma (PCNSL) reported conflicting results. Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and…

P20.16.B FIRST-LINE TREATMENT OF MEDULLOBLASTOMA IN ADOLESCENTS AND ADULTS - UPDATE ON THE EORTC 1634-BTG/NOA-23 PHASE II TRIAL Open

Peter Hau, Kristian W. Pajtler, Felix Sahm, Benedikt Wiestler, Clemens Seidel , et al. · 2023

BACKGROUND Medulloblastoma is a common brain malignancy in children. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high a…

P20.11.A TEMPORAL MUSCLE THICKNESS AS PROGNOSTIC MARKER IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - A VALIDATION STUDY Open

Matthijs van der Meulen, Renske Gahrmann, Bronno van der Holt, Jeanette K. Doorduijn, Samar Issa , et al. · 2023

BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare, aggressive diffuse large B-cell lymphoma, confined to the central nervous system. Age and performance status are validated prognostic variables in PCNSL. Frailty may als…

JS01.4.A CENTRALIZED CRANIOSPINAL PROTON THERAPY FOR MEDULLOBLASTOMA PATIENTS; AN EVALUATION OF THE CARE INFRASTRUCTURE IN THE NETHERLANDS Open

Liseth L. van den Berg, John H. Maduro, A. Bannink-Gawryszuk, Ingeborg Bosma, Stefan Both , et al. · 2023

BACKGROUND The introduction of proton radiotherapy in the Netherlands resulted in the centralization of proton craniospinal irradiation (pCSI) for patients with medulloblastoma (MB) to a single center. For optimal outcome of MB patients, t…

Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma Open

Margaretha G.M. Roemer, Tim van de Brug, Erik Bosch, Daniella R. A. I. Berry, Nathalie J. Hijmering , et al. · 2023

Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol Open

L. Bleeker, Mathilde C.M. Kouwenhoven, Iris de Heer, Birgit I. Lissenberg‐Witte, Annette Gijsbers , et al. · 2023

Purpose Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Methods Adult medulloblast…

Is there a future for maintenance temozolomide chemotherapy in PCNSL? Open

Jacoline E. C. Bromberg, Jeanette K. Doorduijn · 2023

Journal Article Is there a future for maintenance temozolomide chemotherapy in PCNSL? Get access Jacoline E C Bromberg, Jacoline E C Bromberg Department of Neuro-Oncology, Erasmus MC University Medical Center Cancer Institute, Rotterdam, t…

Reviewer Lists Open

Stephen Joseph, B Ramón, Francisco Barajas, Dieta Chetan Bettegowda, Bruno Brandsma , et al. · 2023

Journal Article Reviewer Lists Get access Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 214–216, https://doi.org/10.1093/neuonc/noac277 Published: 05 January 2023 Article history Corrected and typeset: 05 January 2023 Published: …

Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma Open

Margaretha G.M. Roemer, Tim van de Brug, Erik Bosch, Daniella R. A. I. Berry, Nathalie J. Hijmering , et al. · 2022

To understand the clinical significance of the tumor microenvironment (TME), it is essential to study the interactions between malignant and non-malignant cells in clinical specimens. Here, we established a computational framework for a mu…

OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study Open

Jacoline E. C. Bromberg, Samar Issa, Bronno van der Holt, Monique C. Minnema, Tatjana Seute , et al. · 2022

Background The efficacy of rituximab in Primary CNS Lymphoma (PCNSL) is still under debate. We performed an international randomized phase III study to investigate the efficacy of rituximab when added to methotrexate, BCNU, teniposide and …

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) Open

Khê Hoang‐Xuan, Martina Deckert, Andrés J.M. Ferreri, Julia Furtner, Jaime Gállego Pérez‐Larraya , et al. · 2022

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advan…

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY Open

Jeanette K. Doorduijn, Samar Issa, Bronno van der Holt, M. Minnema, Tatjana Seute , et al. · 2022

Background: The efficacy of rituximab in Primary CNS Lymphoma (PCNSL) is still under debate. We performed an international randomized phase III study to investigate the efficacy of rituximab when added to methotrexate, BCNU, teniposide and…

Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors Open

Vincent K.Y. Ho, Anja Gijtenbeek, Michiel Wagemakers, Walter Taal, Myra E. van Linde , et al. · 2022

Background Ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors occur relative frequently in children, but are rare central nervous system (CNS) tumors in adults. In this population-based survey, we esta…

Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) Open

Matthias Preusser, Antonio Silvani, Émilie Le Rhun, Riccardo Soffietti, Giuseppe Lombardi , et al. · 2021

Background No systemic treatment has been established for meningioma progressing after local therapies. Methods This randomized, multicenter, open-label, phase II study included adult patients with recurrent WHO grade 2 or 3 meningioma. Pa…

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 Open

Peter Hau, Didier Frappaz, Elizabeth Hovey, Martin G. McCabe, Kristian W. Pajtler , et al. · 2021

Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling lon…

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma Open

Ruben Van Dijck, Jeanette K. Doorduijn, Jacoline E. C. Bromberg · 2021

Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methot…

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma Open

Matthijs van der Meulen, Linda Dirven, Katerina Bakunina, Martin J. van den Bent, Samar Issa , et al. · 2021

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial Open

Matthijs van der Meulen, Linda Dirven, Esther J. J. Habets, Katerina Bakunina, Marion Smits , et al. · 2021

Background To analyze the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma (PCNSL). Methods One hundred and ninety-nine patie…

MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial Open

Andrés J.M. Ferreri, Jeanette K. Doorduijn, Alessandro Re, Maria Giuseppina Cabras, Jeffery Smith , et al. · 2021

Extent of radiological response does not reflect survival in primary central nervous system lymphoma Open

Matthijs van der Meulen, Alida A. Postma, Marion Smits, Katerina Bakunina, Monique C. Minnema , et al. · 2021

Background In primary central nervous system lymphoma (PCNSL), small enhancing lesions can persist after treatment. It is unknown whether a difference in response category (complete response [CR], complete response unconfirmed [CRu], or pa…

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 Open

Peter Hau, orcid, Didier Frappaz, Elizabeth Hovey, Martin G. McCabe , et al. · 2021

Simple Summary Medulloblastoma is rare after puberty. Among several molecular subgroups that have been described, the sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal population and can be targeted with smoothen…

Jacoline E. C. Bromberg YOU? Author Swipe